Cns.

Neurology

A. Major Long Answer Questions

1. Cerebrovascular Accident (Stroke)
2. Epilepsy
3. Meningitis
4. Encephalitis
5. Meningoencephalitis (Comparison & Overview)
6. Raised Intracranial Pressure (ICP)
7. Headache – Migraine, Tension, Cluster
8. Parkinson’s Disease
9. Peripheral Neuropathy
10. Guillain–Barré Syndrome (GBS)
11. Myasthenia Gravis
12. Multiple Sclerosis (MS)
13. Motor Neuron Disease (MND)
14. Coma – Causes and Approach to Unconscious Patient
15. Subarachnoid Hemorrhage
16. Epileptic Status / Status Epilepticus
17. Pyogenic and tuburcular meningitis
18. Generalised grand Mall epilepsy and trigger factors for seizure

B. Common Short Notes

17. Transient Ischemic Attack (TIA)
18. Bell’s Palsy
19. Trigeminal Neuralgia
20. Alzheimer’s Disease
21. Horner’s Syndrome
22. Brain Death Criteria
23. Lumbar Puncture – Indications and CSF Findings

⚕️ 1. CEREBROVASCULAR ACCIDENT (STROKE)

1. Definition

A cerebrovascular accident (CVA) or stroke is a sudden onset of focal neurological

deficit resulting from disturbance in blood supply to the brain, lasting >24 hours
or leading to death, with no apparent cause other than vascular.

2. Types
1. Ischemic stroke (85%)
• Due to thrombosis or embolism causing brain infarction.
2. Hemorrhagic stroke (15%)
• Due to rupture of cerebral blood vessel → intracerebral or subarachnoid
bleed.

3. Risk Factors
1. Hypertension.
 2. Diabetes mellitus.
3. Smoking.
4. Dyslipidemia.
5. Atrial fibrillation, valvular disease.
6. Previous TIA.
7. Obesity, sedentary lifestyle.

4. Clinical Features
1. Sudden onset of weakness, numbness, or paralysis (usually one side).
2. Facial deviation, slurred speech, or aphasia.
3. Loss of balance or vision.
4. Altered sensorium or coma in severe cases.
5. Headache and vomiting in hemorrhagic strokes.

5. Neurological Findings
1. Hemiplegia or hemiparesis.
2. Upper motor neuron facial palsy.
3. Aphasia if dominant hemisphere involved.
4. Hemianopia (visual field loss).
5. Ataxia or vertigo (brainstem or cerebellar lesions).

6. Investigations
1. CT scan brain (non-contrast):
• To differentiate ischemic from hemorrhagic stroke.
2. MRI brain: more sensitive for early infarcts.
3. Blood sugar, lipids, coagulation profile.
4. ECG and echocardiography (embolic source).
5. Carotid Doppler for stenosis.

7. Management

A. Immediate Care
1. Airway, breathing, circulation (ABC) stabilization.
2. Bed rest with head elevation (30°).
3. Monitor BP and glucose.
4. Avoid lowering BP unless >220/120 mmHg or candidate for thrombolysis.

B. Ischemic Stroke
1. Thrombolysis:
• IV alteplase (tPA) within 4.5 hours of onset.
2. Antiplatelets: Aspirin 150–300 mg/day.
3. Statins: Atorvastatin high dose.
4. Control risk factors (BP, diabetes, smoking).
5. Rehabilitation: physiotherapy, speech therapy.

C. Hemorrhagic Stroke
1. Control BP cautiously (<140 mmHg systolic).
2. Stop anticoagulants.
3. Surgical evacuation if large hematoma or cerebellar bleed.
4. Mannitol for raised ICP.
⸻

8. Complications
1. Raised intracranial pressure.
2. Aspiration pneumonia.
3. Deep vein thrombosis.
4. Pressure sores.
5. Seizures.
6. Depression or dementia.

9. Prevention
1. Control hypertension and diabetes.
2. Stop smoking, manage lipids.
3. Antiplatelets in high-risk patients.
4. Carotid endarterectomy for significant stenosis.

Quick Recall:
• Stroke = sudden focal deficit due to vascular cause.
• Ischemic > hemorrhagic.
• CT first, tPA within 4.5 hrs, aspirin, rehab.

⚕️ 2. EPILEPSY

1. Definition

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked

seizures due to abnormal electrical discharges in the brain.

2. Classification

A. Generalized Seizures
1. Tonic-clonic (grand mal): loss of consciousness, tonic rigidity →
clonic jerks → postictal confusion.
2. Absence (petit mal): brief staring, no fall, common in children.
3. Myoclonic: sudden jerks of muscles.
4. Atonic: sudden loss of tone → falls.

B. Focal (Partial) Seizures

1. Simple partial: no loss of consciousness.
2. Complex partial: impaired awareness, automatisms (lip-smacking,
fumbling).

3. Causes
1. Idiopathic (genetic).
2. Structural brain lesions – trauma, tumor, stroke.
3. Infections – meningitis, neurocysticercosis.
4. Metabolic – hypoglycemia, hypocalcemia.
 5. Drug withdrawal (alcohol, sedatives).

4. Clinical Features
• Sudden episodic convulsions, loss of consciousness, incontinence,
tongue bite, postictal drowsiness.

5. Investigations
1. EEG: epileptiform discharges.
2. CT/MRI brain: structural lesions.
3. Electrolytes, glucose, calcium.

6. Management

A. General Measures
1. Identify and treat underlying cause.
2. Avoid sleep deprivation and alcohol.
3. Family education about seizure first aid.

B. Drug Therapy (Monotherapy preferred)

1. Generalized tonic-clonic: Sodium valproate or levetiracetam.
2. Focal seizures: Carbamazepine.
3. Absence: Ethosuximide.
4. Myoclonic: Valproate.
5. Status epilepticus: IV diazepam → phenytoin → phenobarbital.

C. Surgical Treatment
• For refractory epilepsy (temporal lobectomy, vagal nerve stimulator).

7. Prognosis
• 70–80% achieve good control.
• Drug withdrawal only after 2 seizure-free years.

Quick Recall:
• Epilepsy = recurrent seizures.
• EEG diagnosis, single drug therapy.
• Valproate = broad spectrum; carbamazepine = focal.

⚕️ 3. MENINGITIS

1. Definition

Inflammation of the meninges (pia and arachnoid mater) caused by infection, leading
to fever, headache, neck stiffness, and altered sensorium.

⸻
2. Types
1. Bacterial (Pyogenic) – acute, severe.
2. Viral (Aseptic) – self-limiting.
3. Tuberculous (TBM) – chronic, subacute.

3. Etiology
• Bacterial: Neisseria meningitidis, Streptococcus pneumoniae, H.
influenzae.
• Viral: Enteroviruses, HSV.
• Tuberculous: Mycobacterium tuberculosis.

4. Clinical Features
1. Fever, severe headache, vomiting.
2. Neck rigidity and photophobia.
3. Kernig’s and Brudzinski’s signs positive.
4. Altered consciousness, seizures.
5. Papilledema in raised ICP.
6. Focal neurological signs (TBM).

5. Investigations
1. Lumbar puncture (CSF analysis):
• Bacterial: turbid, ↑ protein, ↓ glucose, neutrophils.
• Viral: clear, mild ↑ protein, normal glucose, lymphocytes.
• TB: clear/xanthochromic, ↑ protein, ↓ glucose, lymphocytes.
2. CSF culture for organism.
3. CT/MRI brain before LP if raised ICP suspected.
4. Blood culture.

6. Management

A. Empirical Antibiotics (Start Immediately)

• Ceftriaxone + Vancomycin (add ampicillin if >50 years or
immunocompromised).
• Modify as per culture.

B. Supportive
1. IV fluids, nutrition, antipyretics.
2. Mannitol if raised ICP.
3. Dexamethasone (esp. pneumococcal meningitis).
4. Anticonvulsants if seizures.

C. For TB Meningitis
• ATT for 9–12 months + steroids for 6–8 weeks.

7. Complications
1. Hydrocephalus.
2. Cranial nerve palsy (especially CN VI).
3. Seizures and mental retardation.
 4. Deafness (pneumococcal).
5. Death in untreated cases.

Quick Recall:
• Triad: fever + neck stiffness + altered sensorium.
• CSF: turbid (bacterial), clear (viral), lymphocytic (TB).
• Treat immediately with ceftriaxone + vancomycin.

Would you like me to continue directly with Part 2 (covering Encephalitis, Raised
ICP, and Headache syndromes) next?

⚕️ 4. ENCEPHALITIS

1. Definition

Encephalitis is an acute inflammation of brain parenchyma, usually caused by viral

infection, leading to fever, altered sensorium, and focal neurological signs.

2. Etiology
1. Viral:
• Herpes simplex virus (most common).
• Japanese encephalitis virus.
• Enteroviruses, rabies, CMV, HIV.
2. Post-infectious or autoimmune causes.

3. Pathophysiology
1. Virus enters CNS → neuronal necrosis, cerebral edema, and inflammation.
2. Herpes virus has predilection for temporal and frontal lobes.

4. Clinical Features
1. Prodrome: fever, malaise, headache, myalgia.
2. CNS involvement:
• Altered consciousness, disorientation, confusion.
• Seizures (common in HSV).
• Focal deficits – aphasia, hemiparesis.
• Behavioral changes or psychosis (temporal lobe).
3. Signs of meningeal irritation may coexist.

5. Investigations
1. CSF: clear, moderate ↑ protein, normal glucose, lymphocytosis.
2. MRI brain: hyperintensity in temporal lobes (HSV).
 3. EEG: periodic sharp waves (in HSV).
4. CSF PCR: confirms viral DNA (especially HSV).
5. Serology / ELISA for specific viruses.

6. Management
1. Empirical antiviral therapy:
• IV Acyclovir 10 mg/kg every 8 hr for 14–21 days (start immediately).
2. Supportive care:
• Maintain airway, hydration, nutrition.
• Antipyretics, anticonvulsants.
• Mannitol for cerebral edema.
3. Steroids: only if severe cerebral edema.

7. Complications
1. Seizures and cognitive deficits.
2. Behavioral changes and memory loss.
3. Coma or death (if untreated HSV).

Quick Recall:
• Fever + confusion + seizures → suspect encephalitis.
• MRI temporal lobe + PCR positive = HSV.
• Start IV acyclovir early.

⚕️ 5. RAISED INTRACRANIAL PRESSURE (ICP)

1. Definition

Raised ICP is defined as intracranial pressure >20 mmHg due to increased brain
tissue, blood, or CSF volume, leading to compression of brain structures.

2. Causes
1. Space-occupying lesions: tumor, abscess, hematoma.
2. Cerebral edema: trauma, hypoxia, encephalitis.
3. Hydrocephalus.
4. Venous sinus thrombosis.

3. Pathophysiology
• The skull is a fixed space (Monro–Kellie doctrine).
• ↑ any component (CSF, blood, tissue) → ↑ ICP → ↓ cerebral perfusion →
ischemia and herniation if untreated.

4. Clinical Features
1. Headache, worse in morning or on coughing.
 2. Vomiting (projectile, without nausea).
3. Papilledema (blurred vision).
4. Altered sensorium or coma.
5. Cushing’s triad:
• Hypertension, bradycardia, irregular respiration.
6. Focal deficits (depending on lesion site).

5. Investigations
1. CT / MRI brain – to identify cause.
2. Fundoscopy – papilledema.
3. Avoid lumbar puncture before imaging (risk of herniation).

6. Management

A. Immediate
1. Head elevation (30°) to enhance venous drainage.
2. Oxygenation and airway maintenance.
3. IV Mannitol (0.5–1 g/kg) – osmotic diuretic.
4. Hypertonic saline if mannitol contraindicated.
5. Avoid hypotonic fluids.
6. Sedation and analgesia.

B. Specific
1. Treat underlying cause:
• Remove tumor or abscess.
• Drain CSF if hydrocephalus.
2. Steroids (dexamethasone) – for tumors or edema (not trauma).
3. Hyperventilation (short term) to reduce CO₂.

7. Complications
1. Brain herniation (fatal).
2. Optic atrophy and blindness.
3. Permanent neurological deficits.

Quick Recall:
• Triad: headache + vomiting + papilledema.
• Mannitol, head elevation, treat cause, avoid LP.

⚕️ 6. HEADACHE (MIGRAINE, TENSION, CLUSTER)

1. Definition

Headache is pain felt in the head, scalp, or neck region, arising from irritation
of pain-sensitive structures.
Common primary types: Migraine, Tension, and Cluster headaches.

⸻
2. MIGRAINE

A. Definition

Recurrent attacks of throbbing headache, often unilateral, associated with nausea,

vomiting, and photophobia.

B. Types
1. Migraine with aura (classic).
2. Migraine without aura (common).

C. Clinical Features
1. Prodrome: visual aura (flashing lights, zig-zag lines).
2. Unilateral throbbing pain lasting 4–72 hours.
3. Nausea, photophobia, phonophobia.
4. Relieved by sleep or quiet dark room.

D. Triggers

Stress, lack of sleep, menstruation, chocolate, cheese, alcohol.

E. Treatment
1. Acute attack:
• NSAIDs, triptans (sumatriptan), antiemetics.
2. Prophylaxis:
• Propranolol, topiramate, or amitriptyline.
3. Avoid triggers, regular sleep and meals.

3. TENSION HEADACHE

A. Features
1. Bilateral tight band-like pain around forehead or occiput.
2. Associated with stress or anxiety.
3. No vomiting or visual aura.

B. Treatment
1. Reassurance, stress management.
2. Analgesics (NSAIDs, paracetamol).
3. Amitriptyline for chronic cases.

4. CLUSTER HEADACHE

A. Features
1. Severe unilateral orbital or temporal pain lasting 15–180 minutes.
2. Occurs in clusters (daily attacks for weeks, then remission).
3. Associated with lacrimation, nasal congestion, ptosis (Horner’s
syndrome).

B. Treatment
1. Acute: Oxygen inhalation or subcutaneous sumatriptan.
2. Prophylaxis: Verapamil, corticosteroids.

⸻
Quick Recall:
• Migraine = throbbing unilateral ± aura.
• Tension = tight band, stress-related.
• Cluster = severe orbital pain + lacrimation.

⚕️ 7. PARKINSON’S DISEASE

1. Definition

A chronic, progressive neurodegenerative disorder of the extrapyramidal system,

caused by dopamine deficiency in the substantia nigra, leading to bradykinesia,
rigidity, tremor, and postural instability.

2. Etiology
1. Idiopathic (primary Parkinson’s disease) – most common.
2. Secondary: drugs (neuroleptics, reserpine), toxins (CO, Mn), trauma,
encephalitis, vascular lesions.
3. Genetic forms in young-onset cases.

3. Pathophysiology

Degeneration of dopaminergic neurons in substantia nigra pars compacta → ↓ dopamine

in basal ganglia → imbalance between dopamine and acetylcholine → motor
dysfunction.

4. Clinical Features
1. Rest tremor (“pill-rolling”), decreases on movement.
2. Rigidity (lead-pipe or cog-wheel).
3. Bradykinesia: slowness of movement, masked face, reduced blink.
4. Postural instability → falls.
5. Festinating gait, stooped posture, micrographia.
6. Non-motor: depression, constipation, anosmia, sleep disturbance.

5. Diagnosis

Clinical—based on the presence of ≥2 of 4 cardinal features (tremor, rigidity,

bradykinesia, postural instability).
MRI may exclude secondary causes.

6. Treatment

A. Pharmacologic
1. Levodopa + Carbidopa – gold standard.
 2. Dopamine agonists: pramipexole, ropinirole.
3. MAO-B inhibitors: selegiline, rasagiline.
4. COMT inhibitors: entacapone.
5. Anticholinergics: trihexyphenidyl (for tremor in young).
6. Amantadine for dyskinesia.

B. Non-pharmacologic

Physiotherapy, gait training, occupational therapy.

C. Surgical

Deep-brain stimulation (subthalamic nucleus or globus pallidus) in refractory

cases.

7. Complications

Motor fluctuations, dyskinesias, dementia, depression, autonomic dysfunction.

Quick Recall:
• Triad: tremor + rigidity + bradykinesia.
• Levodopa–carbidopa mainstay; DBS if resistant.

⚕️ 8. PERIPHERAL NEUROPATHY

1. Definition

A disorder of peripheral nerves causing sensory, motor, or autonomic dysfunction.

2. Causes
1. Metabolic: diabetes – most common.
2. Nutritional: B₁₂, B₆, thiamine deficiency.
3. Toxic: alcohol, heavy metals, drugs (isoniazid).
4. Infectious: leprosy, HIV.
5. Hereditary: Charcot–Marie–Tooth disease.
6. Autoimmune: GBS, vasculitis.

3. Types
1. Polyneuropathy: diffuse, symmetrical (e.g. diabetic).
2. Mononeuropathy: single nerve (e.g. carpal tunnel).
3. Mononeuritis multiplex: patchy involvement (vasculitis).

4. Clinical Features
1. Sensory: numbness, tingling, glove-and-stocking loss, burning.
2. Motor: weakness, foot-drop, wasting.
 3. Autonomic: orthostatic hypotension, impotence, anhidrosis.
4. Reflexes: reduced or absent ankle/knee jerks.

5. Investigations
1. Blood glucose, vitamin B₁₂, thyroid, renal/liver function.
2. Nerve conduction studies – slowed conduction.
3. Nerve biopsy (selected cases).
4. CSF if GBS suspected.

6. Management
1. Treat cause: control diabetes, stop toxins, replace vitamins.
2. Pain relief: gabapentin, pregabalin, amitriptyline.
3. Physiotherapy and foot care.

Quick Recall:
• Commonest cause = diabetes.
• Symptoms = glove-and-stocking sensory loss.
• Manage cause + neuropathic pain relief.

⚕️ 9. GUILLAIN–BARRÉ SYNDROME (GBS)

1. Definition

An acute immune-mediated demyelinating polyneuropathy, characterized by rapidly

progressive, symmetrical ascending weakness often following an infection.

2. Etiology
1. Post-infectious: Campylobacter jejuni, CMV, EBV, Mycoplasma.
2. Vaccination or surgery (rare).

3. Pathophysiology

Autoimmune response damages myelin sheath of peripheral nerves, causing conduction

block.
Variants:
• AIDP (classical), AMAN (axonal), Miller Fisher syndrome
(ophthalmoplegia, ataxia, areflexia).

4. Clinical Features
1. Ascending flaccid paralysis: starts in legs → arms → face → respiratory
muscles.
2. Areflexia.
3. Sensory symptoms: paresthesia, mild pain.
 4. Cranial-nerve palsies (especially facial).
5. Autonomic dysfunction: tachy/bradycardia, BP fluctuations.
6. May lead to respiratory failure (bulbar involvement).

5. Investigations
1. CSF: albuminocytologic dissociation – ↑ protein, normal cells.
2. Nerve-conduction studies: demyelination pattern.
3. Pulmonary function tests: monitor vital capacity.

6. Management
1. Hospitalization – monitor respiration and autonomic function.
2. Specific therapy:
• IV Immunoglobulin (IVIG) 0.4 g/kg/day × 5 days, or
• Plasmapheresis (5 sessions).
3. Supportive:
• Mechanical ventilation if vital capacity < 15 mL/kg.
• DVT prophylaxis, physiotherapy.

7. Prognosis
1. Recovery in 3–6 months in most.
2. 5% mortality (respiratory failure, arrhythmias).
3. Poor outcome: old age, rapid onset, need for ventilation.

Quick Recall:
• Post-infectious ascending paralysis with areflexia.
• CSF: ↑ protein, no cells.
• Treat with IVIG or plasmapheresis.

⚕️ 10. MYASTHENIA GRAVIS

1. Definition

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction,

characterized by fluctuating muscle weakness that increases with activity and
improves with rest.

2. Etiopathogenesis
1. Autoantibodies against acetylcholine receptors (AChR) on postsynaptic
membrane → decreased number of functional receptors.
2. Muscle contraction fails due to impaired transmission.
3. Often associated with thymic hyperplasia or thymoma.

⸻
3. Clinical Features
1. Fatigable weakness – worsens with use, improves with rest.
2. Ocular symptoms: ptosis and diplopia (most common initial signs).
3. Bulbar involvement: nasal speech, dysphagia.
4. Facial weakness, expressionless face.
5. Proximal limb weakness.
6. Respiratory muscle weakness (myasthenic crisis).
7. Normal sensation and reflexes.

4. Investigations
1. Edrophonium (Tensilon) test: transient improvement after IV
edrophonium.
2. Ice-pack test: improvement of ptosis after cooling.
3. Serum AChR antibodies (positive in ~85%).
4. Repetitive nerve stimulation: decremental response.
5. CT/MRI chest: to detect thymoma.

5. Treatment

A. Symptomatic
1. Anticholinesterase drugs: Pyridostigmine 30–60 mg 4–6 hourly.

B. Immunosuppressive
1. Corticosteroids (prednisolone).
2. Azathioprine / Mycophenolate mofetil as steroid-sparing agents.

C. Thymectomy

Indicated in:
• Thymoma (always).
• Generalized MG <60 years, or poor drug response.

D. Crisis Management
1. Myasthenic crisis: ventilatory support + IVIG or plasmapheresis.
2. Cholinergic crisis: stop drugs, give atropine if needed.

6. Prognosis
1. Excellent with therapy.
2. Myasthenic crisis may be life-threatening but reversible.

Quick Recall:
• Fatigable weakness + ptosis + diplopia.
• AChR antibodies positive; treat with pyridostigmine + steroids ±
thymectomy.

⚕️ 11. MULTIPLE SCLEROSIS (MS)

⸻
1. Definition

A chronic demyelinating disease of the CNS, characterized by disseminated plaques

of demyelination in the brain and spinal cord, causing neurological deficits
separated in time and space.

2. Etiology
1. Autoimmune-mediated destruction of myelin.
2. Triggered by genetic predisposition (HLA-DR2) and viral infection
(EBV).
3. Common in young females (20–40 yrs).

3. Pathophysiology
• Immune attack on myelin → conduction block → plaques in optic nerves,
brainstem, periventricular white matter, spinal cord.

4. Clinical Features
1. Visual symptoms:
• Optic neuritis (painful vision loss).
• Diplopia.
2. Motor: weakness, spasticity, hyperreflexia.
3. Sensory: numbness, paresthesia.
4. Cerebellar: ataxia, tremor.
5. Bladder involvement: urgency, incontinence.
6. Lhermitte’s sign: electric shock on neck flexion.
7. Fatigue and cognitive dysfunction.

5. Diagnostic Criteria
1. Dissemination in time and space – ≥2 attacks at ≥2 sites.
2. MRI brain/spine: multiple demyelinating plaques.
3. CSF: oligoclonal bands (↑ IgG).
4. Evoked potentials: delayed conduction.

6. Treatment

A. Acute Relapse
• IV methylprednisolone 1 g/day × 3–5 days, taper with oral steroids.

B. Disease-Modifying Therapy
• Interferon-β, glatiramer acetate, fingolimod, or natalizumab to reduce
relapses.

C. Symptomatic
• Baclofen/tizanidine for spasticity.
• Oxybutynin for bladder symptoms.
• Antidepressants for mood.

⸻
7. Prognosis
• Variable course: relapsing–remitting most common.
• May progress to secondary progressive disease.

Quick Recall:
• Young female + optic neuritis + multiple CNS lesions.
• MRI shows plaques; steroids for relapse, interferon for prevention.

⚕️ 12. MOTOR NEURON DISEASE (MND)

1. Definition

A progressive degenerative disorder of motor neurons involving both upper and lower
motor neurons, leading to muscle wasting, weakness, and spasticity.

2. Types
1. Amyotrophic Lateral Sclerosis (ALS): most common, affects both UMN and
LMN.
2. Progressive Bulbar Palsy.
3. Primary Lateral Sclerosis (UMN).
4. Progressive Muscular Atrophy (LMN).

3. Etiology
1. Idiopathic (sporadic majority).
2. Genetic (SOD1 mutation).
3. Environmental toxins, oxidative stress (theories).

4. Clinical Features
1. Asymmetrical weakness and wasting – hands → legs.
2. Fasciculations (visible twitches).
3. Spasticity and brisk reflexes (UMN).
4. Dysarthria, dysphagia (bulbar).
5. No sensory or sphincter involvement.
6. No ocular movement weakness (distinguishes from MG).

5. Investigations
1. Electromyography (EMG): denervation and reinnervation.
2. MRI brain/spine: exclude other causes.
3. Serum CPK: may be slightly raised.

6. Management
1. Disease-modifying: Riluzole (glutamate inhibitor) prolongs survival.
 2. Supportive:
• Physiotherapy, speech therapy.
• Non-invasive ventilation for respiratory failure.
• Nutritional support via feeding tube.

7. Prognosis

Progressive, fatal within 3–5 years (usually due to respiratory failure).

Quick Recall:
• Mixed UMN + LMN signs, no sensory loss.
• Riluzole + supportive care.

⚕️ 13. COMA & APPROACH TO UNCONSCIOUS PATIENT

1. Definition

Coma is a state of unarousable unresponsiveness, where the patient cannot be

awakened by any stimulus.

2. Causes

A. Structural (Brain Lesions)

1. Stroke or intracerebral hemorrhage.
2. Trauma (head injury).
3. Tumor or abscess.

B. Metabolic / Toxic
1. Hypoglycemia, diabetic ketoacidosis.
2. Hypoxia, hypercapnia.
3. Drug overdose (sedatives, alcohol).
4. Hepatic or uremic encephalopathy.
5. Sepsis, electrolyte imbalance.

3. Initial Assessment (ABCs)

1. Airway: ensure patency, intubate if needed.
2. Breathing: check oxygen saturation.
3. Circulation: pulse, BP, IV access.
4. Blood glucose: check immediately (give IV dextrose if low).
5. Rule out trauma or meningitis.

4. Clinical Examination
1. Level of consciousness: Glasgow Coma Scale (GCS).
2. Pupils:
• Pinpoint → pontine lesion or opioids.
 • Dilated → herniation or atropine.
3. Motor response: localizing, decorticate or decerebrate posturing.
4. Brainstem reflexes: corneal, gag, oculocephalic.
5. Meningeal signs if infection suspected.

5. Investigations
1. Blood: glucose, electrolytes, renal/liver function, ABG, toxicology.
2. CT / MRI brain: to rule out structural cause.
3. Lumbar puncture: if meningitis or encephalitis suspected.
4. EEG: to detect non-convulsive seizures.

6. Management
1. Stabilize vitals and treat reversible causes (hypoglycemia, hypoxia).
2. Avoid hypotension and hyperthermia.
3. Treat raised ICP if present (mannitol, head elevation).
4. Specific therapy:
• Naloxone for opioid toxicity.
• Thiamine before glucose in alcoholics.
• Antibiotics for meningitis/encephalitis.
5. Nursing care: prevent aspiration, bedsores, DVT.

7. Prognosis

Depends on etiology and duration of coma; prolonged coma (>3 weeks) has poor
outcome.

Quick Recall:
• Coma = unarousable unconsciousness.
• Assess ABC, glucose, pupils, GCS.
• Treat reversible causes first.

⚕️ 14. SUBARACHNOID HEMORRHAGE (SAH)

1. Definition

Subarachnoid hemorrhage is bleeding into the subarachnoid space (between arachnoid

and pia mater), usually due to rupture of an intracranial aneurysm.

2. Etiology
1. Berry aneurysm rupture (most common cause – at Circle of Willis).
2. Arteriovenous malformation (AVM).
3. Head trauma.
4. Bleeding disorders or anticoagulant use.
⸻

3. Clinical Features
1. Sudden, severe “thunderclap” headache – worst of life.
2. Vomiting and neck stiffness.
3. Photophobia.
4. Loss of consciousness or seizures.
5. Meningeal signs: Kernig’s, Brudzinski’s positive.
6. Focal deficits or cranial nerve palsy (esp. CN III).

4. Investigations
1. CT brain (non-contrast): shows subarachnoid blood (most sensitive
within 24 h).
2. Lumbar puncture:
• If CT negative, shows xanthochromic CSF (after 12 h).
3. CT/MR angiography: to locate aneurysm.
4. CBC, coagulation profile.

5. Management

A. General
1. Bed rest and BP control (systolic <140 mmHg).
2. Nimodipine (calcium channel blocker) to prevent vasospasm.
3. Analgesics and antiemetics.
4. Avoid anticoagulants.

B. Definitive
1. Surgical clipping or endovascular coiling of aneurysm.
2. Monitor for complications: rebleed, hydrocephalus, vasospasm.

6. Complications
1. Rebleeding (within 24–48 h).
2. Cerebral vasospasm → ischemia.
3. Hydrocephalus.
4. Hyponatremia (SIADH).

7. Prognosis

Mortality ~30–50%. Early intervention improves outcome.

Quick Recall:
• Sudden thunderclap headache → CT brain → Nimodipine + clip/coil.

⚕️ 15. STATUS EPILEPTICUS

⸻
1. Definition

A medical emergency defined as seizure lasting >5 minutes or ≥2 seizures without

recovery of consciousness between them.

2. Etiology
1. Non-compliance or withdrawal of antiepileptic drugs.
2. CNS infections, trauma, stroke.
3. Metabolic: hypoglycemia, hyponatremia, hypocalcemia.
4. Alcohol withdrawal.

3. Pathophysiology

Prolonged seizure → continuous neuronal excitation → hypoxia, acidosis, and

neuronal injury → risk of death.

4. Clinical Features
1. Continuous generalized tonic-clonic movements.
2. Unconsciousness, cyanosis, tongue bite.
3. Autonomic instability – tachycardia, hypertension, hyperthermia.

5. Management (Stepwise Emergency Protocol)

A. Initial (0–5 min)

1. Ensure airway, breathing, circulation.
2. Administer oxygen.
3. Check blood glucose; give 100 mg IV thiamine + 25–50 mL 50% dextrose.

B. First-line (5–10 min)

• IV Diazepam 10 mg slowly, or Lorazepam 4 mg IV (preferred).
• If no IV access → Midazolam IM.

C. Second-line (10–30 min)

• IV Phenytoin 20 mg/kg (max 50 mg/min) or Fosphenytoin.
• Alternative: Valproate or Levetiracetam IV.

D. Third-line (Refractory >30 min)

• IV Midazolam infusion, Propofol, or Phenobarbital.
• Intubation and mechanical ventilation in ICU.

E. Supportive
• Monitor ECG, BP, temperature.
• Treat underlying cause (infection, electrolyte imbalance).

6. Complications

Hypoxia, acidosis, rhabdomyolysis, aspiration, brain damage.

⸻

7. Prognosis

Mortality 10–20%; early control crucial.

Quick Recall:
• Emergency! >5 min seizure.
• 1st: Lorazepam → 2nd: Phenytoin → 3rd: Phenobarbital/Propofol.

🧠 1. PYOGENIC AND TUBERCULAR MENINGITIS

A. PYOGENIC (BACTERIAL) MENINGITIS

1. Definition

Pyogenic meningitis is an acute, purulent inflammation of the meninges and

cerebrospinal fluid (CSF) caused by bacterial infection, leading to fever,
headache, neck stiffness, and altered sensorium.

2. Etiology

Common causative organisms:

• Adults: Streptococcus pneumoniae, Neisseria meningitidis.
• Neonates: Group B Streptococcus, E. coli, Listeria monocytogenes.
• Elderly or immunocompromised: Listeria, Gram-negative bacilli.
• Post-neurosurgery: Staphylococcus aureus, Pseudomonas.

3. Pathophysiology
• Bacteria invade the subarachnoid space through blood or direct
extension (otitis media, sinusitis, skull fracture).
• Inflammation → exudate formation → obstruction of CSF flow → raised
intracranial pressure (ICP).
• Cytokine release causes vasculitis and cerebral edema, leading to
neuronal injury.

4. Clinical Features

A. General:
• Sudden onset of high fever and severe headache.
• Neck stiffness and photophobia.
• Vomiting (often projectile).
• Altered consciousness ranging from confusion to coma.

B. Meningeal Signs:
• Kernig’s sign: pain on extending knee with hip flexed.
• Brudzinski’s sign: passive neck flexion causes hip and knee flexion.
C. Neurological:
• Seizures, focal deficits, cranial nerve palsies (especially VI).

D. Others:
• Petechial rash (meningococcal meningitis).
• Papilledema in raised ICP.

5. Investigations
1. CSF Examination (after ruling out raised ICP):
• Appearance: turbid, purulent.
• Cell count: high neutrophils.
• Protein: markedly increased.
• Sugar: decreased (<40 mg/dL).
• Gram stain and culture: identify organism.
2. Blood tests: leukocytosis, high ESR/CRP.
3. CT/MRI Brain: before LP if focal deficit or papilledema (to exclude
mass lesion).

6. Complications
• Cerebral edema and herniation.
• Cranial nerve palsies (esp. VI, VII, VIII).
• Seizures, hydrocephalus.
• Hearing loss (post-meningitic).
• Death if untreated.

7. Management

A. Immediate Empirical Antibiotics (start before CSF results):

• Adults:
• Ceftriaxone or Cefotaxime + Vancomycin.
• Add Ampicillin if >50 years (cover Listeria).
• Neonates:
• Ampicillin + Cefotaxime or Gentamicin.

B. Supportive Therapy:
• IV fluids, antipyretics.
• Mannitol for raised ICP.
• Anticonvulsants for seizures.
• Dexamethasone to reduce inflammation (especially in pneumococcal
meningitis).

C. Prevention:
• Vaccination against H. influenzae type B, Neisseria meningitidis, and
Streptococcus pneumoniae.

✅ Key Exam Line:

“Pyogenic meningitis is acute bacterial inflammation of meninges causing fever,
neck stiffness, and altered sensorium; CSF shows high neutrophils, low sugar, high
protein; treated with IV ceftriaxone + vancomycin.”
⸻

B. TUBERCULAR MENINGITIS (TBM)

1. Definition

Tubercular meningitis is a chronic granulomatous inflammation of the meninges

caused by Mycobacterium tuberculosis, commonly affecting the base of the brain.

2. Pathogenesis
• Occurs due to rupture of a Rich focus (caseous lesion) from brain or
meninges into subarachnoid space.
• Leads to exudate at the base of brain, vasculitis of arteries, and
obstruction of CSF pathways → hydrocephalus.

3. Clinical Stages

Stage I – Prodromal (1–2 weeks):

• Low-grade fever, malaise, headache, vomiting, irritability.

Stage II – Meningitic (established):

• Neck stiffness, photophobia.
• Cranial nerve palsies (esp. III, VI).
• Altered sensorium.

Stage III – Paralytic (late):

• Stupor, coma, hemiplegia, seizures, decerebrate rigidity.

4. Investigations
1. CSF Examination:
• Clear or slightly opalescent, cobweb coagulum on standing.
• Cells: 50–500 cells/mm³, lymphocytic predominance.
• Protein: elevated (100–500 mg/dL).
• Sugar: decreased (<40 mg/dL).
• ADA (adenosine deaminase): increased.
• PCR or GeneXpert for M. tuberculosis.
2. Imaging:
• CT/MRI: basal meningeal enhancement, hydrocephalus, tuberculomas.
3. Mantoux test: positive.
4. Chest X-ray: may show pulmonary TB.

5. Management

A. Anti-Tubercular Therapy (ATT):

• Intensive phase (2 months): Isoniazid + Rifampicin + Pyrazinamide +
Ethambutol.
• Continuation phase (7–10 months): Isoniazid + Rifampicin.
• Duration: total 9–12 months.
B. Corticosteroids:
• Dexamethasone or Prednisolone for 4–6 weeks → reduce inflammation and
prevent hydrocephalus.

C. Supportive Therapy:
• Mannitol for raised ICP, anticonvulsants if seizures.
• Physiotherapy and nutrition.

6. Complications
• Hydrocephalus.
• Cranial nerve palsies (III, VI, VII).
• Hemiplegia, seizures, mental retardation.
• Death if untreated.

✅ Key Exam Line:

“Tubercular meningitis is chronic basal meningitis with lymphocytic CSF, low sugar,
and high protein; treated with ATT for 9–12 months and corticosteroids.”

⚡ 2. GENERALIZED TONIC–CLONIC (GRAND MAL) EPILEPSY

1. Definition

Generalized tonic–clonic (grand mal) epilepsy is a seizure disorder characterized

by sudden loss of consciousness with generalized tonic and clonic convulsions, due
to abnormal, synchronous neuronal discharges involving both hemispheres.

2. Etiology
• Primary (Idiopathic): genetic predisposition, no structural lesion.
• Secondary (Symptomatic):
• Head injury, stroke, brain tumor.
• CNS infections (meningitis, encephalitis).
• Metabolic causes: hypoglycemia, uremia, electrolyte imbalance.
• Alcohol withdrawal, drug intoxication.

3. Clinical Phases

A. Aura (sometimes absent): brief warning (odd smell, visual flash).

B. Tonic Phase:
• Sudden loss of consciousness.
• Generalized muscle rigidity.
• Eyes rolled up, cyanosis, cry due to air expulsion.
• Lasts 10–20 seconds.

C. Clonic Phase:
• Rhythmic jerking of limbs.
• Tongue biting, frothing, incontinence.
 • Lasts 30–60 seconds.

D. Postictal Phase:
• Deep sleep, confusion, headache, muscle soreness.

4. Diagnosis
• Clinical diagnosis based on witness account.
• EEG: generalized spike-and-wave discharges.
• MRI brain: rule out structural lesion.
• Blood tests: glucose, electrolytes, calcium.

5. Management

A. Acute Seizure (Emergency):

• Protect airway, turn patient to side.
• IV diazepam 10 mg or lorazepam 4 mg slow IV.
• If persistent: IV phenytoin or levetiracetam.

B. Long-term Therapy:
• Valproate (drug of choice) for generalized seizures.
• Alternatives: Levetiracetam, Lamotrigine, Topiramate.
• Educate on adherence and avoid driving until seizure-free for 1 year.

6. Trigger Factors for Seizures

• Sleep deprivation.
• Alcohol intake or withdrawal.
• Flashing lights (photosensitivity).
• Emotional stress.
• Hypoglycemia or missed medication.
• Fever or infection.

✅ Key Exam Line:

“Generalized tonic–clonic epilepsy presents with sudden loss of consciousness,
tonic rigidity, and clonic jerks; valproate is drug of choice; avoid triggers like
alcohol and sleep deprivation.”

⚕️ SHORT NOTES (17–23)

17. TRANSIENT ISCHEMIC ATTACK (TIA)

1. Definition: Brief episode of neurological dysfunction due to transient
cerebral ischemia without infarction.
2. Duration: <24 hours (usually <1 hour).
3. Causes: Atherosclerosis, emboli from carotid or heart.
4. Symptoms: sudden weakness, speech loss, vision changes; complete
recovery.
5. Management:
 • Antiplatelets (Aspirin 150 mg).
• Control BP, diabetes, cholesterol.
• Carotid endarterectomy if severe stenosis.
6. Importance: Warning sign for future stroke.

18. BELL’S PALSY

1. Definition: Acute LMN facial nerve palsy causing unilateral facial
paralysis.
2. Cause: idiopathic, viral (HSV).
3. Features:
• Sudden facial droop, inability to close eye, loss of taste (ant. 2/3
tongue).
• No limb weakness or sensory loss.
4. Treatment:
• Prednisolone 1 mg/kg/day × 10 days.
• Eye care (artificial tears, patch).
• Physiotherapy.
5. Prognosis: Most recover within 2–3 weeks.

19. TRIGEMINAL NEURALGIA

1. Definition: Severe, paroxysmal, electric-shock pain along trigeminal
nerve branches (usually maxillary).
2. Triggers: touch, chewing, talking.
3. Causes: idiopathic or vascular compression of nerve root.
4. Treatment:
• Carbamazepine (drug of choice).
• Alternatives: gabapentin, baclofen.
• Microvascular decompression if refractory.

20. ALZHEIMER’S DISEASE

1. Definition: Progressive neurodegenerative dementia characterized by
loss of memory, judgment, and behavior changes.
2. Pathology: amyloid plaques and neurofibrillary tangles.
3. Clinical:
• Gradual memory loss, disorientation, apathy, personality change.
• Preserved motor function until late stage.
4. Diagnosis: clinical + MRI (cortical atrophy).
5. Treatment:
• Cholinesterase inhibitors (donepezil, rivastigmine).
• NMDA antagonist (memantine).
• Supportive and caregiver counseling.

21. HORNER’S SYNDROME

1. Definition: Lesion of sympathetic pathway to the eye →
triad of ptosis, miosis, anhidrosis.
2. Causes:
• Pancoast tumor, carotid dissection, brainstem lesion.
3. Features:
• Ptosis (loss of superior tarsal muscle).
• Miosis (pupil constriction).
• Anhidrosis (loss of sweating).
 4. Diagnosis: clinical + imaging for underlying cause.
5. Treatment: treat cause.

22. BRAIN DEATH – CRITERIA

1. Definition: Irreversible cessation of all brain and brainstem
functions.
2. Prerequisites:
• Known cause, normal temperature, no CNS depressant drugs.
3. Clinical Tests:
• Unresponsive coma.
• Absent brainstem reflexes (pupil, corneal, gag).
• No spontaneous respiration (apnea test).
4. Confirmatory Tests:
• EEG (no activity).
• Absent cerebral blood flow (angiography).
5. Declared after two examinations by qualified physicians.

23. LUMBAR PUNCTURE – INDICATIONS & CSF FINDINGS

1. Definition: Diagnostic procedure involving withdrawal of CSF from
subarachnoid space (L3–L4).
2. Indications:
• Suspected meningitis, SAH (after CT).
• CNS demyelinating disease (MS).
• Measurement of CSF pressure.
3. Contraindications:
• Raised ICP (risk of herniation).
• Local infection, bleeding disorder.
4. Procedure: lateral decubitus position, aseptic technique, measure
opening pressure.
5. Normal CSF: clear, pressure 10–20 cmH₂O, protein 15–45 mg/dL, glucose
2/3 plasma.
6. Abnormal Findings:
• Turbid → bacterial meningitis.
• Xanthochromic → SAH.
• Lymphocytosis → TB or viral.